JP6158078B2 - 薬物感受性、薬物抵抗性および疾患進行の予測のための組成物および方法 - Google Patents

薬物感受性、薬物抵抗性および疾患進行の予測のための組成物および方法 Download PDF

Info

Publication number
JP6158078B2
JP6158078B2 JP2013506214A JP2013506214A JP6158078B2 JP 6158078 B2 JP6158078 B2 JP 6158078B2 JP 2013506214 A JP2013506214 A JP 2013506214A JP 2013506214 A JP2013506214 A JP 2013506214A JP 6158078 B2 JP6158078 B2 JP 6158078B2
Authority
JP
Japan
Prior art keywords
cancer
molecule
cells
sample
disease
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP2013506214A
Other languages
English (en)
Japanese (ja)
Other versions
JP2013525786A5 (enExample
JP2013525786A (ja
Inventor
ダグラス ピー． クラーク
ダグラス ピー． クラーク
アダム シャイオヴィッツ
アダム シャイオヴィッツ
シリロ カブラディラ
シリロ カブラディラ
Original Assignee
バイオマーカー ストラテジーズ リミテッド ライアビリティ カンパニー
バイオマーカー ストラテジーズ リミテッド ライアビリティ カンパニー
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by バイオマーカー ストラテジーズ リミテッド ライアビリティ カンパニー, バイオマーカー ストラテジーズ リミテッド ライアビリティ カンパニー filed Critical バイオマーカー ストラテジーズ リミテッド ライアビリティ カンパニー
Publication of JP2013525786A publication Critical patent/JP2013525786A/ja
Publication of JP2013525786A5 publication Critical patent/JP2013525786A5/ja
Application granted granted Critical
Publication of JP6158078B2 publication Critical patent/JP6158078B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6803—General methods of protein analysis not limited to specific proteins or families of proteins
    • G01N33/6842—Proteomic analysis of subsets of protein mixtures with reduced complexity, e.g. membrane proteins, phosphoproteins, organelle proteins
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/502—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects
    • G01N33/5041—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects involving analysis of members of signalling pathways
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B20/00—ICT specially adapted for functional genomics or proteomics, e.g. genotype-phenotype associations
    • G16B20/20—Allele or variant detection, e.g. single nucleotide polymorphism [SNP] detection
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B5/00—ICT specially adapted for modelling or simulations in systems biology, e.g. gene-regulatory networks, protein interaction networks or metabolic networks
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2440/00—Post-translational modifications [PTMs] in chemical analysis of biological material
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B20/00—ICT specially adapted for functional genomics or proteomics, e.g. genotype-phenotype associations

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Physics & Mathematics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Biotechnology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biophysics (AREA)
  • Analytical Chemistry (AREA)
  • Bioinformatics & Computational Biology (AREA)
  • Cell Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Food Science & Technology (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Theoretical Computer Science (AREA)
  • Evolutionary Biology (AREA)
  • Medical Informatics (AREA)
  • Spectroscopy & Molecular Physics (AREA)
  • Genetics & Genomics (AREA)
  • Toxicology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Physiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Oncology (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
JP2013506214A 2010-04-19 2011-04-18 薬物感受性、薬物抵抗性および疾患進行の予測のための組成物および方法 Expired - Fee Related JP6158078B2 (ja)

Applications Claiming Priority (9)

Application Number Priority Date Filing Date Title
US32571710P 2010-04-19 2010-04-19
US61/325,717 2010-04-19
US35649510P 2010-06-18 2010-06-18
US61/356,495 2010-06-18
US42117810P 2010-12-08 2010-12-08
US61/421,178 2010-12-08
US201161443146P 2011-02-15 2011-02-15
US61/443,146 2011-02-15
PCT/US2011/032935 WO2011133477A2 (en) 2010-04-19 2011-04-18 Compositions and methods for prediction of drug sensitivity, resistance, and disease progression

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2016243869A Division JP6580546B2 (ja) 2010-04-19 2016-12-16 薬物感受性、薬物抵抗性および疾患進行の予測のための組成物および方法

Publications (3)

Publication Number Publication Date
JP2013525786A JP2013525786A (ja) 2013-06-20
JP2013525786A5 JP2013525786A5 (enExample) 2016-06-16
JP6158078B2 true JP6158078B2 (ja) 2017-07-05

Family

ID=44834747

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2013506214A Expired - Fee Related JP6158078B2 (ja) 2010-04-19 2011-04-18 薬物感受性、薬物抵抗性および疾患進行の予測のための組成物および方法
JP2016243869A Expired - Fee Related JP6580546B2 (ja) 2010-04-19 2016-12-16 薬物感受性、薬物抵抗性および疾患進行の予測のための組成物および方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2016243869A Expired - Fee Related JP6580546B2 (ja) 2010-04-19 2016-12-16 薬物感受性、薬物抵抗性および疾患進行の予測のための組成物および方法

Country Status (12)

Country Link
US (1) US9766249B2 (enExample)
EP (1) EP2561368B1 (enExample)
JP (2) JP6158078B2 (enExample)
KR (1) KR101977875B1 (enExample)
CN (2) CN102947706B (enExample)
AU (1) AU2011242990B2 (enExample)
CA (1) CA2795362C (enExample)
ES (1) ES2650674T3 (enExample)
HK (1) HK1258688A1 (enExample)
PL (1) PL2561368T3 (enExample)
SG (1) SG184507A1 (enExample)
WO (1) WO2011133477A2 (enExample)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2294216A4 (en) 2008-05-14 2011-11-23 Dermtech Int DIAGNOSIS OF MELANOMA AND SOLAR LENTIGO BY ANALYSIS OF NUCLEIC ACIDS
CA2767616A1 (en) 2009-07-09 2011-01-13 The Scripps Research Institute Gene expression profiles associated with chronic allograft nephropathy
WO2014145705A2 (en) 2013-03-15 2014-09-18 Battelle Memorial Institute Progression analytics system
CN104152397A (zh) * 2013-05-13 2014-11-19 复旦大学 一种致敏动物的脾细胞模型及其在药物筛选中的用途
GB201314485D0 (en) * 2013-08-13 2013-09-25 Electrophoretics Ltd Materials and methods relating to pancreatic cancer
TW201601753A (zh) * 2013-09-30 2016-01-16 第一三共股份有限公司 蛋白質生物標記及其用途
WO2022187196A1 (en) * 2021-03-02 2022-09-09 Dermtech, Inc. Predicting therapeutic response
US11578373B2 (en) 2019-03-26 2023-02-14 Dermtech, Inc. Gene classifiers and uses thereof in skin cancers
US10443100B2 (en) 2014-05-22 2019-10-15 The Scripps Research Institute Gene expression profiles associated with sub-clinical kidney transplant rejection
US11104951B2 (en) 2014-05-22 2021-08-31 The Scripps Research Institute Molecular signatures for distinguishing liver transplant rejections or injuries
CN104745700A (zh) * 2015-03-27 2015-07-01 南京医科大学 一种食管癌相关甲基化生物标志物及应用
CN107922504B (zh) * 2015-07-07 2021-07-30 豪夫迈·罗氏有限公司 抗HER2抗体-药物缀合物和Bcl-2抑制剂的组合疗法
WO2017136603A1 (en) * 2016-02-02 2017-08-10 Guardant Health, Inc. Cancer evolution detection and diagnostic
CN105524973A (zh) * 2016-03-15 2016-04-27 南京华奥生物医药技术有限公司 利用自体肿瘤与正常配对原代细胞筛选肿瘤药物的方法
CN107091930B (zh) * 2017-03-07 2020-09-15 杭州百凌生物科技有限公司 快速预测和提高非小细胞肺癌细胞对表皮细胞生长因子受体抑制剂敏感性的方法
CN107271672B (zh) * 2017-06-21 2019-01-01 首都医科大学附属北京友谊医院 外泌体p-ERK在制备结直肠癌诊断产品中的应用
KR102094802B1 (ko) * 2017-10-24 2020-03-31 고려대학교 산학협력단 소변 대사체 분석을 이용한 베체트병의 진단방법
CN111417730A (zh) * 2017-11-20 2020-07-14 托雷莫治疗股份公司 诊断方法
TWI683905B (zh) * 2017-11-21 2020-02-01 長庚醫療財團法人高雄長庚紀念醫院 用於檢測川崎氏病的方法及套組以及用於治療川崎氏病的方法
US11976332B2 (en) 2018-02-14 2024-05-07 Dermtech, Inc. Gene classifiers and uses thereof in non-melanoma skin cancers
KR102199141B1 (ko) 2019-05-03 2021-01-06 사회복지법인 삼성생명공익재단 대장암 진단 마커 및 대장암 진단에 필요한 정보를 제공하는 방법
EP4185870A1 (en) * 2020-07-24 2023-05-31 Genentech, Inc. Determining hemodilution of bone marrow aspirates using biomarkers
CN115267165A (zh) * 2022-08-15 2022-11-01 海仕兰(上海)生物科技有限公司 一种悬浮芯片系统及其应用以及基于悬浮芯片系统对肿瘤伴随诊断因子检测方法
KR20240037082A (ko) * 2022-09-14 2024-03-21 아주대학교산학협력단 항암제 내성 측정용 바이오 마커 및 이를 이용한 항암제 내성 예측 정보 제공 방법
CN118130793B (zh) * 2024-02-26 2025-07-29 赣南医科大学 视网膜母细胞瘤的生物标志物cdk12及其应用

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6218122B1 (en) * 1998-06-19 2001-04-17 Rosetta Inpharmatics, Inc. Methods of monitoring disease states and therapies using gene expression profiles
US20060188895A1 (en) * 2004-08-31 2006-08-24 The Johns Hopkins University Rapid prognostic assay for malignancies treated with epidermal growth factor receptor
US8841076B2 (en) * 2005-05-09 2014-09-23 Theranos, Inc. Systems and methods for conducting animal studies
WO2006125143A2 (en) * 2005-05-18 2006-11-23 Novartis Ag Methods for diagnosis and treatment of proliferative disorders mediated by cd40 signaling
WO2006133399A1 (en) 2005-06-08 2006-12-14 Hitachi Chemical Research Center, Inc. METHOD FOR PREDICTING IMMUNE RESPONSE TO NEOPLASTIC DISEASE BASED ON mRNA EXPRESSION PROFILE IN NEOPLASTIC CELLS AND STIMULATED LEUKOCYTES
EP1937314A4 (en) 2005-09-01 2009-01-07 Bristol Myers Squibb Co BIOMARKERS AND PROCEDURE FOR DETERMINING SENSITIVITY FOR VASCULAR ENDOTHEL GROWTH FACTOR RECEPTOR 2 MODULATORS
WO2007143183A2 (en) 2006-06-04 2007-12-13 Soner Altiok Methods for developing and assessing therapeutic agents
PE20090681A1 (es) * 2007-03-02 2009-06-10 Genentech Inc Prediccion de respuesta a un inhibidor her
JP2010536371A (ja) * 2007-08-21 2010-12-02 ノダリティ，インコーポレイテッド 診断方法、予後および治療方法
EP2210080B1 (en) 2007-10-24 2015-01-28 Biomarker Strategies, Llc Improved methods and devices for cellular analysis
EP2220503A1 (en) * 2007-11-30 2010-08-25 Schering Corporation Braf biomarkers

Also Published As

Publication number Publication date
EP2561368A4 (en) 2013-10-09
JP6580546B2 (ja) 2019-09-25
HK1258688A1 (zh) 2019-11-15
PL2561368T4 (pl) 2018-03-30
CN108535465A (zh) 2018-09-14
EP2561368B1 (en) 2017-08-02
EP2561368A2 (en) 2013-02-27
KR101977875B1 (ko) 2019-05-13
AU2011242990A1 (en) 2012-11-01
WO2011133477A2 (en) 2011-10-27
AU2011242990B2 (en) 2015-02-12
CN102947706B (zh) 2018-04-13
PL2561368T3 (pl) 2018-03-30
CA2795362C (en) 2018-03-20
US9766249B2 (en) 2017-09-19
WO2011133477A3 (en) 2012-05-10
JP2017106923A (ja) 2017-06-15
CA2795362A1 (en) 2012-10-02
JP2013525786A (ja) 2013-06-20
SG184507A1 (en) 2012-11-29
US20120094853A1 (en) 2012-04-19
ES2650674T3 (es) 2018-01-19
CN102947706A (zh) 2013-02-27
KR20130095183A (ko) 2013-08-27

Similar Documents

Publication Publication Date Title
JP6580546B2 (ja) 薬物感受性、薬物抵抗性および疾患進行の予測のための組成物および方法
JP7108323B2 (ja) 細胞全体でのアッセイおよび方法
JP6782698B2 (ja) がん患者を診断および処置するためのｅｒｂｂシグナル伝達経路活性の測定方法
Korde et al. Gene expression pathway analysis to predict response to neoadjuvant docetaxel and capecitabine for breast cancer
JP2022081538A (ja) 個別化薬物治療計画の開発方法、及びプロテオミックプロファイルに基づく標的薬物開発
Hyeon et al. Proteogenomic landscape of human pancreatic ductal adenocarcinoma in an Asian population reveals tumor cell-enriched and immune-rich subtypes
JP7264484B2 (ja) 治療剤選択のためのシグナル伝達経路活性の測定方法
WO2010147961A1 (en) Methods and markers for predicting responses to chemotherapy
Bleker de Oliveira et al. Analytical challenges in development of chemoresistance predictors for precision oncology
Lee et al. High-throughput screening for genes that prevent excess DNA replication in human cells and for molecules that inhibit them
Gordon Transcriptional profiling of mesothelioma using microarrays
Bellot et al. Reliability of tumor primary cultures as a model for drug response prediction: expression profiles comparison of tissues versus primary cultures from colorectal cancer patients
US20160259918A1 (en) Computational Approach for Identifying a Combination of Two Drugs
Hoff et al. Reverse phase protein arrays in acute leukemia: investigative and methodological challenges
Shao et al. 443 Protein Typing of Circulating Microvesicles Allows Real-time Monitoring of Glioblastoma Therapy
Ma et al. Identification of gene expression profiles associated with doxorubicin resistance in paired doxorubicin-resistant and doxorubicin-sensitive osteosarcoma cell lines
Lee et al. High-Throughput Chemotherapeutic Drug Screening System for Gastric Cancer (Cure-GA)
Słodkowska et al. Digital pathology in personalized cancer therapy
Suehara Proteomic analysis of soft tissue sarcoma
Zhu et al. Single-cell transcriptome analysis reveals estrogen signaling augments the mitochondrial folate pathway to coordinately fuel purine and polyamine synthesis in breast cancer cells
Awaji Utilization of High Throughput Screening to Identify Therapeutic Targets for Defective MCPH1/BRIT1 Function-Induced Premature Chromosome Condensation in Breast and Ovarian Cancer.
Ramos Characterization of Small Cell Carcinoma of the Ovary, Hypercalcemic Type

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20140403

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20140403

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20141107

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20150107

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20150318

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20150430

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20150501

RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7424

Effective date: 20150512

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20151014

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20160104

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20160212

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20160311

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20160412

A524 Written submission of copy of amendment under article 19 pct

Free format text: JAPANESE INTERMEDIATE CODE: A524

Effective date: 20160412

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20160817

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20161216

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20170203

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20170214

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20170306

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20170406

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20170511

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20170607

R150 Certificate of patent or registration of utility model

Ref document number: 6158078

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

LAPS Cancellation because of no payment of annual fees